他非诺喹用于巴西间日疟控制与消除的建模研究
该建模研究评估在巴西间日疟病例管理中引入他非诺喹对群体传播的影响。模型校准至2018年巴西流行区传播动态,假设伯氨喹与他非诺喹疗效均为71.3%、7天伯氨喹方案依从率66.7%、G6PDd患病率5.5%。
要点
- 他非诺喹单剂方案通过提高依从性改善有效根治率,从而降低间日疟传播。
- 在低传播、低伯氨喹依从率及男性病例为主的地区,他非诺喹影响更大。
- 推广他非诺喹需同步开展G6PDd检测以确保安全。
核心结论
- 在同步推广G6PDd诊断的前提下,他非诺喹可通过提高依从性和增强对新感染的保护来降低间日疟传播。
- 他非诺喹单独可能不足以消除间日疟,但可改善病例管理、预防大量病例并推动实现消除目标。
研究设计与样本
- 采用间日疟传播的数学模型,校准至2018年巴西流行区的传播动态,依据全国疟疾报告数据。
- 治疗路径参数(氯喹、伯氨喹、他非诺喹联合G6PDd检测)来自临床试验数据与文献。
主要发现
- 模型预测他非诺喹推广可提高间日疟病例的有效休眠子清除率,并随时间降低群体传播,不同传播强度地区影响各异。
- 在巴西仅少数地区可实现消除,但2021年推广他非诺喹预计将临床病例平均有效根治率从42%(95% UI 41%-44%)提高至62%(95% UI 54%-68%)。
- 预计传播降低38%(95% UI 7%-99%),2021至2025年累计避免超过214,000例病例。
关键数值与推荐
- 假设伯氨喹和他非诺喹疗效均为71.3%,7天伯氨喹方案依从率66.7%,G6PDd平均患病率5.5%,低代谢者患病率8.1%。
临床怎么用
- 在间日疟病例管理中引入他非诺喹单剂方案,并同步开展G6PDd检测。
- 在低传播、低伯氨喹依从率及工作年龄男性病例为主的地区优先推广他非诺喹。
- 高传播且儿童病例比例高的地区需儿童安全高疗效他非诺喹剂量。
局限性
- 未考虑传播地区外输入病例的作用。
- 依赖报告的临床病例作为社区传播的测量指标。
- 将治疗疗效作为二元条件处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite recent intensification of control measures, Plasmodium vivax poses a major challenge for malaria elimination efforts. Liver-stage hypnozoite parasites that cause relapsing infections can be cleared with primaquine; however, poor treatment adherence undermines drug effectiveness. Tafenoquine, a new single-dose treatment, offers an alternative option for preventing relapses and reducing transmission. In 2018, over 237,000 cases of malaria were reported to the Brazilian health system, of which 91.5% were due to P. vivax. METHODS AND FINDINGS: We evaluated the impact of introducing tafenoquine into case management practices on population-level transmission dynamics using a mathematical model of P. vivax transmission. The model was calibrated to reflect the transmission dynamics of P. vivax endemic settings in Brazil in 2018, informed by nationwide malaria case reporting data. Parameters for treatment pathways with chloroquine, primaquine, and tafenoquine with glucose-6-phosphate dehydrogenase deficiency (G6PDd) testing were informed by clinical trial data and the literature. We assumed 71.3% efficacy for primaquine and tafenoquine, a 66.7% adherence rate to the 7-day primaquine regimen, a mean 5.5% G6PDd prevalence, and 8.1% low metaboliser prevalence. The introduction of tafenoquine is predicted to improve effective hypnozoite clearance among P. vivax cases and reduce population-level transmission over time, with heterogeneous levels of impact across different transmission settings. According to the model, while achieving elimination in only few settings in Brazil, tafenoquine rollout in 2021 is estimated to improve the mean effective radical cure rate from 42% (95% uncertainty interval [UI] 41%-44%) to 62% (95% UI 54%-68%) among clinical cases, leading to a predicted 38% (95% UI 7%-99%) reduction in transmission and over 214,000 cumulative averted cases between 2021 and 2025. Higher impact is predicted in settings with low transmission, low pre-existing primaquine adherence, and a high proportion of cases in working-aged males. High-transmission settings with a high proportion of cases in children would benefit from a safe high-efficacy tafenoquine dose for children. Our methodological limitations include not accounting for the role of imported cases from outside the transmission setting, relying on reported clinical cases as a measurement of community-level transmission, and implementing treatment efficacy as a binary condition. CONCLUSIONS: In our modelling study, we predicted that, provided there is concurrent rollout of G6PDd diagnostics, tafenoquine has the potential to reduce P. vivax transmission by improving effective radical cure through increased adherence and increased protection from new infections. While tafenoquine alone may not be sufficient for P. vivax elimination, its introduction will improve case management, prevent a substantial number of cases, and bring countries closer to achieving malaria elimination goals.
引用
- Nekkab N, Lana R, Lacerda M, et al. Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study. PLoS Med. 2021. PMID: 33891582. doi:10.1371/journal.pmed.1003535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。